CD19 and leukemia: Clinical trials using second-generation CAR-T cells, specifically those expressing anti-CD19 chimeric antigen receptors in autologous T cells, demonstrated robust T cell proliferation and significant efficacy against leukemia in patients with chronic lymphocytic leukemia.